Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

PURPOSE We investigated whether tumor tissue obtained at diagnosis expresses a specific gene profile that is predictive of findings at second-look surgery in patients with epithelial ovarian cancer (EOC). PATIENTS AND METHODS Tumor tissue obtained at the time of diagnosis was profiled with oligonucleotide microarrays. Class prediction analysis was performed in a training set of 24 patients who had undergone a second-look procedure. The resultant predictive signature was then tested on an independent validation set comprised of 36 patients. RESULTS A 93-gene signature referred to as the Chemotherapy Response Profile (CRP) was identified through its association with pathologic complete response. When applied to a separate validation set, the CRP distinguished between patients with unfavorable versus favorable overall survival (median 41 months v not yet reached, respectively, log-rank P = .007), with a median follow-up of 52 months. The signature maintained independent prognostic value in multivariate analysis, controlling for other known prognostic factors such as age, stage, grade, and debulking status. There was no genetic overlap between the CRP and our previously described Ovarian Cancer Prognostic Profile (OCPP), which demonstrated similar prognostic value. The combination of the CRP and OCPP yielded better prognostic discrimination then either profile alone. Genes present in the CRP include BAX, a proapoptotic protein previously associated with chemotherapy response in ovarian cancer. CONCLUSION Identification of a gene expression profile based on pathologic response in EOC provides independent prognostic information and offers potential insights into the mechanism of drug resistance. Efforts to identify a more tailored profile using selected genes from both the CRP and OCPP are underway.

[1]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[3]  David I. Smith,et al.  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.

[4]  Andrea Califano,et al.  Analysis of Gene Expression Microarrays for Phenotype Classification , 2000, ISMB.

[5]  S. Cannistra,et al.  BAX protein expression and clinical outcome in epithelial ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Knudsen,et al.  RB-Dependent S-Phase Response to DNA Damage , 2000, Molecular and Cellular Biology.

[7]  Marie Joseph,et al.  Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yusuke Nakamura,et al.  Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling , 2005, Clinical Cancer Research.

[9]  J. Tukey.  Tightening the clinical trial. , 1993, Controlled clinical trials.

[10]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[11]  Gustavo Stolovitzky,et al.  Genes@Work: an efficient algorithm for pattern discovery and multivariate feature selection in gene expression data , 2004, Bioinform..

[12]  Andrea Califano,et al.  SPLASH: structural pattern localization analysis by sequential histograms , 2000, Bioinform..

[13]  P. Vanderhaeghen,et al.  Ephrin signalling controls brain size by regulating apoptosis of neural progenitors , 2005, Nature.

[14]  S. Korsmeyer,et al.  BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Andrea Califano,et al.  Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. , 2003, The Journal of clinical investigation.

[16]  Shigemi Kinoshita,et al.  Activation of the PKB/AKT pathway by ICAM-2. , 2002, Immunity.

[17]  David Ward,et al.  Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data , 2003, Bioinform..

[18]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[19]  Steven P. Angus,et al.  Analysis of RB action in DNA damage checkpoint response. , 2004, Methods in molecular biology.

[20]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[21]  J. Minna,et al.  The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation , 2002, Molecular and Cellular Biology.

[22]  S. Cannistra,et al.  In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. , 1999, Cancer research.

[23]  Y. Tu,et al.  Gene Expression Dynamics during Germinal Center Transit in B Cells , 2003, Annals of the New York Academy of Sciences.

[24]  Dong-Hyun Kim,et al.  Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. , 2005, Gynecologic oncology.

[25]  M. West,et al.  Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.

[26]  Tony Hunter,et al.  MNK1, a new MAP kinase‐activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates , 1997, The EMBO journal.

[27]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[28]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Wiedenmann,et al.  Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. , 2002, Journal of the National Cancer Institute.

[30]  S. Cannistra,et al.  BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. , 1998, Cancer research.

[31]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[33]  Andrea Califano,et al.  Transcriptional analysis of the B cell germinal center reaction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Jonathan A. Cooper,et al.  Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 , 1997, The EMBO journal.

[35]  Michael Dohn,et al.  Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis , 2001, Oncogene.

[36]  T. Jacks,et al.  RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. , 2004, Nucleic acids research.

[37]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.